TOR in the immune system
- 31 December 2011
- journal article
- review article
- Published by Elsevier BV in Current Opinion in Cell Biology
- Vol. 23 (6), 707-715
- https://doi.org/10.1016/j.ceb.2011.08.006
Abstract
No abstract availableKeywords
This publication has 68 references indexed in Scilit:
- Rapamycin Reverses Cellular Phenotypes and Enhances Mutant Protein Clearance in Hutchinson-Gilford Progeria Syndrome CellsScience Translational Medicine, 2011
- HIF1α–dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cellsThe Journal of Experimental Medicine, 2011
- Direct activation of mTOR in B lymphocytes confers impairment in B‐cell maturation andloss of marginal zone B cellsEuropean Journal of Immunology, 2011
- Origins of CD4+ effector and central memory T cellsNature Immunology, 2011
- Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cellsBlood, 2008
- T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTORProceedings of the National Academy of Sciences of the United States of America, 2008
- Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte traffickingNature Immunology, 2008
- Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fatesThe Journal of Experimental Medicine, 2008
- The AKT–mTOR axis regulates de novo differentiation of CD4+Foxp3+ cellsThe Journal of Experimental Medicine, 2008
- De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTORJournal of Leukocyte Biology, 2008